RBC Capital Sticks to Their Buy Rating for FLSmidth & Co. A/S (0OJA)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Housden covers the Industrials sector, focusing on stocks such as Paccar, FLSmidth & Co. A/S, and Kone Oyj. According to TipRanks, Housden has an average return of 13.0% and a 70.90% success rate on recommended stocks.
Currently, the analyst consensus on FLSmidth & Co. A/S is a Moderate Buy with an average price target of DKK414.20, a 6.37% upside from current levels. In a report released on July 3, Jefferies also maintained a Buy rating on the stock with a DKK440.00 price target.
0OJA market cap is currently DKK22.08B and has a P/E ratio of 18.88.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Analysts' Opinions Are Mixed on These Technology Stocks: Circle Internet Group, Inc. Class A (CRCL) and u-blox Holding AG (OtherUBLXF)
Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Circle Internet Group, Inc. Class A (CRCL – Research Report) and u-blox Holding AG (UBLXF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Circle Internet Group, Inc. Class A (CRCL) Seaport Global analyst Jeff Cantwell reiterated a Buy rating on Circle Internet Group, Inc. Class A today and set a price target of $280.00. The company's shares closed last Friday at $149.26. According to Cantwell is a 5-star analyst with an average return of 11.7% and a 57.5% success rate. Cantwell covers the Technology sector, focusing on stocks such as ACI Worldwide, Fiserv, and Dave. The word on The Street in general, suggests a Hold analyst consensus rating for Circle Internet Group, Inc. Class A with a $174.64 average price target, implying a 23.7% upside from current levels. In a report issued on August 4, Bernstein also maintained a Buy rating on the stock with a $230.00 price target. u-blox Holding AG (UBLXF) Kepler Capital analyst Torsten Sauter maintained a Hold rating on u-blox Holding AG on August 15 and set a price target of CHF105.00. The company's shares closed last Friday at $170.79. According to Sauter is ranked #1974 out of 9981 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for u-blox Holding AG with a $148.36 average price target, representing a -13.1% downside. In a report issued on August 7, UBS also maintained a Hold rating on the stock with a CHF105.00 price target.
Business Insider
an hour ago
- Business Insider
Upcoming Stock Splits This Week (August 18 to August 22)
These are the upcoming stock splits for the week of August 18 to August 22, based on TipRanks' Stock Splits Calendar. A stock split boosts the number of shares each investor holds, but the company's overall market value remains exactly the same. The effect is a lower share price, which often makes the stock more affordable and appealing to retail investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Traditional stock splits are designed to broaden a stock's accessibility by reducing its price per share. But some companies take the opposite route through a reverse stock split. In this case, shares are consolidated rather than divided, reducing the total count and raising the price per share. The company's overall market value remains unchanged, but this tactic is often a lifeline, helping firms stay in compliance with exchange rules, like Nasdaq's minimum price requirement, and sidestep the risk of delisting. Whether the goal is to attract new investors or maintain compliance, these strategic actions send signals that seasoned traders are quick to watch for. Let's take a look at the upcoming stock splits for the week. Salarius Pharmaceuticals (SLRX) – Salarius is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and anemia. On August 14, the company announced a 1-for-15 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split took effect on August 15, with split-adjusted trading beginning on August 18. Entero Therapeutics (ENTO) – Entero, a clinical-stage biopharma focused on targeted, non-systemic gastrointestinal (GI) therapies, is taking steps to secure its Nasdaq listing. On August 14, the company unveiled plans for a 1-for-3 reverse stock split, a move designed to keep its shares in compliance with exchange rules. The adjustment becomes effective August 18. Chanson International Holding (CHSN) – China-based Chanson International operates bakery chains and sells packaged bakery products, frozen dough, and other food items across domestic and international markets. On August 18, the company will implement an 80-for-1 reverse split to get back in line with Nasdaq's minimum bid price rule. LanzaTech Global (LNZA) – LanzaTech Global uses gas fermentation technology to capture carbon emissions and convert them into sustainable fuels and chemicals, partnering with major industrial players worldwide. The company announced a 1-for-100 reverse stock split to meet Nasdaq listing standards, with the split taking effect on August 18, and split-adjusted trading beginning on August 19. GIBO Holdings (GIBO) – GIBO Holdings, headquartered in Singapore, operates an AI-driven animation and entertainment streaming platform that produces and distributes original content while also offering digital media services. The company announced a 200-for-1 reverse split to streamline its capital structure and stay in line with listing requirements, with the split taking effect on August 20. Azitra (AZTR) – Azitra is a clinical-stage biotech company developing genetically engineered therapies and live biotherapeutics for dermatological conditions such as eczema and rare skin diseases. The company announced the 1-for-6.66 reverse stock split in order to bring its share price back above NYSE American's minimum bid requirement, effective on August 21, 2025.
Yahoo
4 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
